A wave of late-stage startups quietly marked down their valuations in Q3

Many startups are overvalued. But because they are also well-stocked with cash, they haven’t had to raise new funding at a lower or flat valuation — yet. However, new data from Carta found that cracks are starting to show.

Startup equity infrastructure platform Carta found that a record number of startup employee stock grants — which are stock option packages offered to individual employees — were repriced in Q3. The total of 18,629 repricings was up 260% from the 7,165 that were repriced in Q2. The only prior quarter that comes close is Q2 2020, with 12,570, when the pandemic started to unfold.

What these repriced share packages tell us is that startups are starting to mark down their internal valuations despite not raising a new round. How? Because employee stock grants are tied to a company’s 409a valuation — a third-party appraisal of a company’s fair market value.

A wave of late-stage startups quietly marked down their valuations in Q3 by Rebecca Szkutak originally published on TechCrunch



from TechCrunch https://ift.tt/NeQ3x4a
via IFTTT

Comments

Post a Comment

Popular posts from this blog

6 investors discuss why AI is more than just a buzzword in biotech

As ChatGPT has so aptly demonstrated, AI is now truly entering the mainstream consciousness. That’s why we weren’t very surprised when a slew of investors told us they rarely see a biotech startup that doesn’t incorporate AI in some form or other these days. “Most of the companies we have seen have an AI component to support the discovery or development processes,” Francisco Dopazo, a general partner at Humboldt Fund told TechCrunch recently. But despite becoming quite the buzzword, AI’s apparent ubiquity in biotech isn’t actually driving deal flow or higher valuations. So to get a better idea of how AI is affecting biotech in 2022, we asked six investors to tell us what they look for in a biotech startup today. For Franck Lescure, a partner at Elaia Partners, in biotech, having an AI component isn’t an automatic deal closer. “We do not favor biotech startups with extant AI over those without: Bio-revolution is not only digital. Digital is one tool; the other major tool is the livin
Read more

Voiceflow, a Canada-based SaaS platform that lets companies launch their own voice and chat bots, raises $20M Series A led by Felicis Ventures (Igor Bosilkovski/Forbes)

Image
Igor Bosilkovski / Forbes : Voiceflow, a Canada-based SaaS platform that lets companies launch their own voice and chat bots, raises $20M Series A led by Felicis Ventures   —  Canadian collaborative conversational AI tool Voiceflow announced today that it has raised $20 million in a Series A round led by Felicis Ventures. from Techmeme https://ift.tt/3rFQ9St via IFTTT
Read more

Ex-staffers say Twitter's mass firing of security staff and growing reliance on automation will help China and other authoritarian regimes in silencing critics (Adam Rawnsley/Rolling Stone)

Image
Adam Rawnsley / Rolling Stone : Ex-staffers say Twitter's mass firing of security staff and growing reliance on automation will help China and other authoritarian regimes in silencing critics   —  Elon's mass firing of security staff and increased reliance on automation is going to make it easier for tyrants to shout … from Techmeme https://ift.tt/xQsF2ef via IFTTT
Read more